Tianjin hematology hospital

Hematology Hospital of Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences), hereinafter referred to as Tianjin Hematology Hospital, was established in 1957 by Professor Deng Jiadong, the founder of Chinese hematology. It moved to Sichuan in the 1970s and relocated in 1982. Back to Tianjin, China. The hospital is the only tertiary first-class blood disease specialist hospital in the country, and it is also the largest national scientific research blood disease professional medical institution integrating medical treatment, scientific research, teaching, and industry.

As a tertiary first-class specialized hospital, it currently has 795 beds, and has anemia diagnosis and treatment center, leukemia diagnosis and treatment center, thrombosis and hemostasis diagnosis and treatment center, stem cell transplantation center, lymphoma diagnosis and treatment center, MDS diagnosis and treatment center, children’s blood disease diagnosis and treatment center, comprehensive diagnosis and treatment Center, Regenerative Medicine Diagnosis and Treatment Center, Blood Disease Emergency Center, Critical Care Medicine Diagnosis and Treatment Center, Hematopathology Diagnosis Center and Clinical Testing Center, with a complete range of specialties, and the number of annual diagnosis and treatment exceeded 200,000.

It is the top institution for the diagnosis and treatment of blood diseases in China. In 2010- In 2022, it won the first place in the hospital specialty reputation list (hematology) for 13 consecutive years. The hospital is characterized by hematology nursing specialty, and launched the Ministry of Health’s “High-quality Nursing Service Demonstration Project” earlier, and has successively won the advanced unit of Tianjin’s health system “Quality Nursing Service Demonstration Project” and the first batch of listed “High-quality Nursing Service Hospitals” .

Since its establishment, the Institute has undertaken more than 1,100 scientific research projects, including 460 national-level projects and more than 350 provincial-level projects. Currently, there are 292 research projects in the institute, and the research funding is about 230 million yuan. It has accumulatively won 109 achievement awards above the provincial and ministerial level, including 24 national awards, 67 authorized invention patents, published 103 monographs, and a total of 1,238 papers included in SCI (data as of November 2021).

Founded the “Chinese Journal of Hematology,” relying on the English journal “Blood Science,” established by the State Key Laboratory of Experimental Hematology, which was included in the DOAJ database and selected as a high-starting new journal of the China Science and Technology Journal Excellence Action Plan. Since the selection, it has won the first place in the ranking list of Chinese hospital science and technology value (hematology) for 9 consecutive years.

As a tertiary-A specialist hospital, it currently has 804 beds and offers a comprehensive range of specialized centers, including:

• Anemia Diagnosis and Treatment Center: Specializes in diagnosing and treating various forms of anemia.
• Leukemia Diagnosis and Treatment Center: Focuses on the diagnosis and management of different types of leukemia.
• Thrombosis and Hemostasis Diagnosis and Treatment Center: Dedicated to disorders related to blood clotting and bleeding.
• Stem Cell Transplantation Center: Provides stem cell transplantation services for various hematological conditions.
• Lymphoma Diagnosis and Treatment Center: Specializes in lymphatic system tumors such as malignant lymphoma, multiple myeloma, and acute/chronic lymphocytic leukemia.
• Myelodysplastic Syndromes (MDS) Diagnosis and Treatment Center: Focuses on diagnosing and treating MDS.
• Pediatric Hematology Diagnosis and Treatment Center: Caters to hematological disorders in children.
• Comprehensive Diagnosis and Treatment Center: Offers integrated care for various blood diseases.
• Regenerative Medicine Diagnosis and Treatment Center: Explores regenerative therapies for hematological conditions.
• Hematology Emergency Center: Provides emergency care for acute hematological issues.
• Critical Care Medical Diagnosis and Treatment Center: Manages critically ill patients with blood diseases.
• Hematopathology Diagnostic Center: Specializes in the pathological diagnosis of blood diseases.
• Clinical Testing Center: Offers comprehensive laboratory testing services.

With a complete set of specialties, the hospital handles over 300,000 diagnoses and treatments annually, making it a top institution for hematological diseases in China. From 2010 to 2022, it ranked first in the China Hospital Specialty Reputation List (Hematology) for 13 consecutive years. The hospital is also recognized for its high-quality nursing services, having initiated the “Demonstration Project of High-quality Nursing Service” by the Ministry of Health and being awarded as one of the first batch of “High-quality Nursing Service Hospitals” in Tianjin.

The Lymphoma Diagnosis and Treatment Center, for instance, comprises multiple wards and laboratories, staffed by a high-level clinical diagnosis, treatment, and research team. Clinical treatment at the center is characterized by precise diagnosis and overall treatment stratified by prognosis. The laboratory focuses on the molecular pathogenesis and effective treatment strategies of lymphoid tumors, emphasizing the effects and mechanisms of genetic abnormalities and immune microenvironment alterations on the occurrence, development, and drug resistance of lymphoma and myeloma.

The hospital also offers advanced therapies such as CAR-T cell therapy for multiple myeloma, exemplified by Fucaso® (Equecabtagene Autoleucel Injection), the world’s first approved fully human CAR-T therapy. This therapy boasts strong efficacy, durable persistence, and excellent safety, providing hope for patients with ultra-high-risk relapsed or refractory multiple myeloma.

In summary, Tianjin Hematology Hospital stands as a leading institution in China for the diagnosis, treatment, and research of hematological diseases, offering a comprehensive range of specialized services and advanced therapies to patients.

The Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, also known as Tianjin Hematology Hospital, is a premier institution in China dedicated to the diagnosis, treatment, and research of hematological diseases. Established in 1957 by Professor Deng Jiadong, the hospital has evolved into a comprehensive facility integrating medical care, scientific research, education, and health services.

Location and Facilities

Situated at No. 288 Nanjing Road, Heping District, Tianjin, the hospital operates as a tertiary first-class specialized hospital with a capacity of 795 beds. It encompasses various specialized centers, including those for anemia, leukemia, thrombosis and hemostasis, stem cell transplantation, lymphoma, myelodysplastic syndromes (MDS), pediatric hematology, comprehensive diagnosis and treatment, regenerative medicine, hematology emergencies, critical care, hematopathology diagnostics, and clinical testing. Collectively, these centers handle over 200,000 patient diagnoses and treatments annually, underscoring the hospital’s prominence in China’s hematology field.

Human Resources and Expertise

The hospital boasts a robust team of 1,361 employees, including 209 professionals with senior technical titles. This diverse team ensures comprehensive patient care and contributes significantly to the hospital’s research endeavors.

Research and Technological Infrastructure

The hospital is equipped with six national-level platforms:

• The State Key Laboratory of Experimental Hematology
• The National Stem Cell Engineering Technology Research Center
• The National Engineering Research Center for Cell Products
• The National Stem Cell Engineering Product Industrialization Base
• A demonstration base for training innovative talents by the Ministry of Science and Technology
• A national key subject of pharmacology and cell and molecular biology

These platforms facilitate advanced research and development in hematology and related fields.

Educational Collaborations

In addition to its clinical and research functions, the hospital serves as a teaching hospital affiliated with Nankai University School of Medicine, reflecting its commitment to medical education and the cultivation of future healthcare professionals.

Recent Developments

The hospital has expanded its infrastructure with the development of the Tuanbo Campus. In June 2024, a public tender was announced for the substation operation and maintenance project at this campus, indicating ongoing enhancements to its facilities.

In summary, Tianjin Hematology Hospital’s infrastructure is characterized by its extensive facilities, specialized centers, advanced research platforms, and a highly qualified team, all dedicated to providing exceptional care in hematology.

The Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), commonly known as Tianjin Hematology Hospital, is located at:

📍 No. 288 Nanjing Road, Heping District, Tianjin, China

This hospital is a leading national-level institution specializing in hematological diseases, integrating medical treatment, scientific research, education, and healthcare services. Let me know if you need more details! 😊

The Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, commonly known as Tianjin Hematology Hospital, is located at:

No. 288 Nanjing Road, Heping District, Tianjin, 300020, China

The Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, commonly known as Tianjin Hematology Hospital, is a premier institution in China dedicated to the diagnosis, treatment, and research of hematological diseases. Established in 1957 by Professor Deng Jiadong, the hospital has developed a comprehensive infrastructure to support its multifaceted services.

Clinical Facilities

The hospital operates as a tertiary, first-class specialized hospital with a capacity of 795 beds. It encompasses various specialized centers, including those for anemia, leukemia, thrombosis and hemostasis, stem cell transplantation, lymphoma, myelodysplastic syndromes (MDS), pediatric hematology, comprehensive diagnosis and treatment, regenerative medicine, hematology emergencies, critical care, hematopathology diagnostics, and clinical testing. Collectively, these centers handle over 300,000 patient diagnoses and treatments annually, underscoring the hospital’s prominence in China’s hematology field.

Specialized Departments

One notable department is the lymphoma diagnosis and treatment center, which includes multiple wards and laboratories. The center has a high-level clinical diagnosis, treatment, and research team comprising professionals with senior and deputy senior titles. The clinical treatment at the center is characterized by precise diagnosis and overall treatment stratified by prognosis. The laboratory focuses on the molecular pathogenesis and effective treatment strategies of lymphoid tumors, emphasizing the effects and mechanisms of genetic abnormalities and immune microenvironment alterations on the occurrence, development, and drug resistance of lymphoma and myeloma.

Research and Technological Infrastructure

The hospital is equipped with six national-level platforms:

• The State Key Laboratory of Experimental Hematology
• The National Stem Cell Engineering Technology Research Center
• The National Engineering Research Center for Cell Products
• The National Stem Cell Engineering Product Industrialization Base
• A demonstration base for training innovative talents by the Ministry of Science and Technology
• A national key subject of pharmacology and cell and molecular biology

These platforms facilitate advanced research and development in hematology and related fields.

Human Resources and Expertise

The hospital boasts a robust team of 1,361 employees, including 209 professionals with senior technical titles. This diverse team ensures comprehensive patient care and contributes significantly to the hospital’s research endeavors.

Educational Collaborations

In addition to its clinical and research functions, the hospital serves as a teaching hospital affiliated with Nankai University School of Medicine, reflecting its commitment to medical education and the cultivation of future healthcare professionals.

Recent Developments

The hospital has expanded its infrastructure with the development of the Tuanbo Campus. In June 2024, a public tender was announced for the substation operation and maintenance project at this campus, indicating ongoing enhancements to its facilities.

In summary, the infrastructure of Tianjin Hematology Hospital is characterized by its extensive facilities, specialized centers, advanced research platforms, and a highly qualified team, all dedicated to providing exceptional care in hematology.